SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-036150
Filing Date
2024-03-26
Accepted
2024-03-26 07:07:54
Documents
14
Period of Report
2024-03-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K mura-20240326.htm   iXBRL 8-K 49443
2 EX-99.1 mura-ex99_1.htm EX-99.1 168057
3 GRAPHIC img134125358_0.jpg GRAPHIC 2944
4 GRAPHIC img134125358_1.jpg GRAPHIC 2944
  Complete submission text file 0000950170-24-036150.txt   356243

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mura-20240326.xsd EX-101.SCH 28023
17 EXTRACTED XBRL INSTANCE DOCUMENT mura-20240326_htm.xml XML 4682
Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41837 | Film No.: 24780881
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)